Analysts count on revenue increase Pharming

Tomorrow the Dutch Pharming will publish its past quarters figures. For this year Pharming 's revenue will be around 285.73 million euros. This is according to the average of the analysts' estimates. The expected revenue would be a record for the company. This is rather significant more than 2023's revenue of 245.32 million euros.

Historical revenues and results Pharming plus estimates 2023

Pharming office Lead © Pharming

The analysts expect for 2024 a net loss of 0 million euros. The majority of the analysts expects for this year a profit per share of 1 cent. The price/earnings-ratio therefore equals a very high 90.

For this year analysts don't expect the company to pay a dividend. The average dividend yield of the biotech companies is an attractive 3.55 percent.

Latest estimates around 81 euros

Based on the current number of outstanding shares Pharming 's market capitalization 590.71 million euros.

Historical stock prices Pharming2007-2024

Analist.nl Nieuwsdienst: +31 084-0032-842
nieuws@analist.nl

Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. Analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.